_id
690dadc2ccc777a4e85d0a37
Ticker
ALVO
Name
Alvotech
Exchange
NASDAQ
Address
9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.alvotech.com
Description
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Last Close
4.86
Volume
31066
Current Price
4.81
Change
-0.11
Last Updated
2026-01-20T15:15:14.839Z
Image
data:image/webp;base64,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
Ipo Date
2022-06-16T00:00:00.000Z
Market Cap
1533077632
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.7589454545454545
Sentiment Sources
22
Rating
4
Target Price
22.1667
Strong Buy
2
Buy
0
Hold
2
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
113953000
Cost Of Revenue
35028000
Gross Profit
78925000
Operating Expenses
77564000
Operating Income
1361000
Interest Expense
36259000
Pretax Income
-6031000
Net Income
-5218000
Eps
-0.017379759219989743
Dividends Per Share
-
Shares Outstanding
311601154
Income Tax Expense
-813000
EBITDA
3685000
Operating Margin
1.1943520574271849
Total Other Income Expense Net
-7392000
Cash
42848000
Short Term Investments
-
Receivables
121351000
Inventories
207729000
Total Current Assets
432006000
Property Plant Equipment
494180000
Total Assets
1409178000
Payables
91628000
Short Term Debt
56019000
Long Term Debt
1081626000
Total Liabilities
1585941000
Equity
-176763000
Bs_currency_symbol
USD
Depreciation
10282000
Change In Working Capital
-59132000
Cash From Operations
-55575000
Capital Expenditures
18926000
Cash From Investing
-39451000
Cash From Financing
-13245000
Net Change In Cash
-108604000
Cf_currency_symbol
USD
PE
21.3913
PB
-8.169849042446666
ROE
2.9519752436878757
ROA
-0.370286791306705
FCF
-74501000
Fcf Percent
-0.6537870876589471
Piotroski FScore
0
Health Score
17
Deep Value Investing Score
1.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.8
Garp Investing Score
1
Growth Investing Score
1.5
Momentum Investing Score
6.5
Net Net Investing Score
0.5
Quality Investing Score
1
Value Investing Score
2
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
113953000
Quarters > 0 > income Statement > cost Of Revenue
35028000
Quarters > 0 > income Statement > gross Profit
78925000
Quarters > 0 > income Statement > operating Expenses
77564000
Quarters > 0 > income Statement > operating Income
1361000
Quarters > 0 > income Statement > interest Expense
36259000
Quarters > 0 > income Statement > pretax Income
-6031000
Quarters > 0 > income Statement > net Income
-5218000
Quarters > 0 > income Statement > eps
-0.017379759219989743
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
300234309
Quarters > 0 > income Statement > income Tax Expense
-813000
Quarters > 0 > income Statement > EBITDA
3685000
Quarters > 0 > income Statement > operating Margin
1.1943520574271849
Quarters > 0 > income Statement > total Other Income Expense Net
-7392000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
42848000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
121351000
Quarters > 0 > balance Sheet > inventories
207729000
Quarters > 0 > balance Sheet > total Current Assets
432006000
Quarters > 0 > balance Sheet > property Plant Equipment
494180000
Quarters > 0 > balance Sheet > total Assets
1409178000
Quarters > 0 > balance Sheet > payables
91628000
Quarters > 0 > balance Sheet > short Term Debt
56019000
Quarters > 0 > balance Sheet > long Term Debt
1081626000
Quarters > 0 > balance Sheet > total Liabilities
1585941000
Quarters > 0 > balance Sheet > equity
-176763000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-5252000
Quarters > 0 > cash Flow > depreciation
10282000
Quarters > 0 > cash Flow > change In Working Capital
-59132000
Quarters > 0 > cash Flow > cash From Operations
-55575000
Quarters > 0 > cash Flow > capital Expenditures
18926000
Quarters > 0 > cash Flow > cash From Investing
-39451000
Quarters > 0 > cash Flow > cash From Financing
-13245000
Quarters > 0 > cash Flow > net Change In Cash
-108604000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.017379759219989743
Quarters > 0 > ratios > PB
-8.169849042446666
Quarters > 0 > ratios > ROE
2.9519752436878757
Quarters > 0 > ratios > ROA
-0.370286791306705
Quarters > 0 > ratios > FCF
-74501000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-0.6537870876589471
Quarters > 0 > health Score
17
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
173239000
Quarters > 1 > income Statement > cost Of Revenue
73825000
Quarters > 1 > income Statement > gross Profit
99414000
Quarters > 1 > income Statement > operating Expenses
81357000
Quarters > 1 > income Statement > operating Income
18057000
Quarters > 1 > income Statement > interest Expense
36651000
Quarters > 1 > income Statement > pretax Income
9310000
Quarters > 1 > income Statement > net Income
32038000
Quarters > 1 > income Statement > eps
0.10223650606003395
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
313371429
Quarters > 1 > income Statement > income Tax Expense
-22728000
Quarters > 1 > income Statement > EBITDA
51742000
Quarters > 1 > income Statement > operating Margin
10.423172611248045
Quarters > 1 > income Statement > total Other Income Expense Net
-8747000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
151452000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
180411000
Quarters > 1 > balance Sheet > inventories
155490000
Quarters > 1 > balance Sheet > total Current Assets
509461000
Quarters > 1 > balance Sheet > property Plant Equipment
441077000
Quarters > 1 > balance Sheet > total Assets
1392754000
Quarters > 1 > balance Sheet > payables
84282000
Quarters > 1 > balance Sheet > short Term Debt
59617000
Quarters > 1 > balance Sheet > long Term Debt
1072138000
Quarters > 1 > balance Sheet > total Liabilities
1566082000
Quarters > 1 > balance Sheet > equity
-173328000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
32037999
Quarters > 1 > cash Flow > depreciation
8897000
Quarters > 1 > cash Flow > change In Working Capital
24825000
Quarters > 1 > cash Flow > cash From Operations
55742000
Quarters > 1 > cash Flow > capital Expenditures
13618000
Quarters > 1 > cash Flow > cash From Investing
-28603000
Quarters > 1 > cash Flow > cash From Financing
83147000
Quarters > 1 > cash Flow > net Change In Cash
112908000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
0.10223650606003395
Quarters > 1 > ratios > PB
-8.696324733972583
Quarters > 1 > ratios > ROE
-18.484030277854703
Quarters > 1 > ratios > ROA
2.300334445278922
Quarters > 1 > ratios > FCF
42124000
Quarters > 1 > ratios > Piotroski FScore
3
Quarters > 1 > ratios > fcf Percent
0.24315540957867454
Quarters > 1 > health Score
52
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
132765000
Quarters > 2 > income Statement > cost Of Revenue
65447000
Quarters > 2 > income Statement > gross Profit
67318000
Quarters > 2 > income Statement > operating Expenses
56736000
Quarters > 2 > income Statement > operating Income
10582000
Quarters > 2 > income Statement > interest Expense
35539000
Quarters > 2 > income Statement > pretax Income
93421000
Quarters > 2 > income Statement > net Income
109680000
Quarters > 2 > income Statement > eps
0.3499999995213348
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
313371429
Quarters > 2 > income Statement > income Tax Expense
-16259000
Quarters > 2 > income Statement > EBITDA
137219000
Quarters > 2 > income Statement > operating Margin
7.970474146047528
Quarters > 2 > income Statement > total Other Income Expense Net
82839000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
38544000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
228751000
Quarters > 2 > balance Sheet > inventories
142074000
Quarters > 2 > balance Sheet > total Current Assets
458872000
Quarters > 2 > balance Sheet > property Plant Equipment
422912000
Quarters > 2 > balance Sheet > total Assets
1245462000
Quarters > 2 > balance Sheet > payables
67887000
Quarters > 2 > balance Sheet > short Term Debt
43820000
Quarters > 2 > balance Sheet > long Term Debt
1063972000
Quarters > 2 > balance Sheet > total Liabilities
1547749000
Quarters > 2 > balance Sheet > equity
-302287000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
109680000
Quarters > 2 > cash Flow > depreciation
8259000
Quarters > 2 > cash Flow > change In Working Capital
-3450000
Quarters > 2 > cash Flow > cash From Operations
12549000
Quarters > 2 > cash Flow > capital Expenditures
23370000
Quarters > 2 > cash Flow > cash From Investing
-20395000
Quarters > 2 > cash Flow > cash From Financing
-5839000
Quarters > 2 > cash Flow > net Change In Cash
-12884000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
0.3499999995213348
Quarters > 2 > ratios > PB
-4.986375773652191
Quarters > 2 > ratios > ROE
-36.283399550758055
Quarters > 2 > ratios > ROA
8.8063706480005
Quarters > 2 > ratios > FCF
-10821000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-0.08150491469890409
Quarters > 2 > health Score
39
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
151205000
Quarters > 3 > income Statement > cost Of Revenue
80330000
Quarters > 3 > income Statement > gross Profit
70875000
Quarters > 3 > income Statement > operating Expenses
57404000
Quarters > 3 > income Statement > operating Income
13471000
Quarters > 3 > income Statement > interest Expense
159198000
Quarters > 3 > income Statement > pretax Income
-44441000
Quarters > 3 > income Statement > net Income
-66967000
Quarters > 3 > income Statement > eps
-0.2218878076306033
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
301805677
Quarters > 3 > income Statement > income Tax Expense
22526000
Quarters > 3 > income Statement > EBITDA
-119982000
Quarters > 3 > income Statement > operating Margin
8.909096921398103
Quarters > 3 > income Statement > total Other Income Expense Net
-57912000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
51428000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
251719000
Quarters > 3 > balance Sheet > inventories
127889000
Quarters > 3 > balance Sheet > total Current Assets
455020000
Quarters > 3 > balance Sheet > property Plant Equipment
409744000
Quarters > 3 > balance Sheet > total Assets
1221400000
Quarters > 3 > balance Sheet > payables
67126000
Quarters > 3 > balance Sheet > short Term Debt
42217000
Quarters > 3 > balance Sheet > long Term Debt
1035882000
Quarters > 3 > balance Sheet > total Liabilities
1634171000
Quarters > 3 > balance Sheet > equity
-412771000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-66967000
Quarters > 3 > cash Flow > depreciation
8155000
Quarters > 3 > cash Flow > change In Working Capital
-59207000
Quarters > 3 > cash Flow > cash From Operations
-39202000
Quarters > 3 > cash Flow > capital Expenditures
31052000
Quarters > 3 > cash Flow > cash From Investing
-31052000
Quarters > 3 > cash Flow > cash From Financing
4296000
Quarters > 3 > cash Flow > net Change In Cash
-66846000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.2218878076306033
Quarters > 3 > ratios > PB
-3.5169265921540025
Quarters > 3 > ratios > ROE
16.223765719975482
Quarters > 3 > ratios > ROA
-5.482806615359424
Quarters > 3 > ratios > FCF
-70254000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.4646274924771006
Quarters > 3 > health Score
28
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
489682000
Annuals > 0 > income Statement > cost Of Revenue
185309000
Annuals > 0 > income Statement > gross Profit
304373000
Annuals > 0 > income Statement > operating Expenses
234729000
Annuals > 0 > income Statement > operating Income
69644000
Annuals > 0 > income Statement > interest Expense
157601000
Annuals > 0 > income Statement > pretax Income
-217563000
Annuals > 0 > income Statement > net Income
-231864000
Annuals > 0 > income Statement > eps
-0.8654077526372441
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
267924570
Annuals > 0 > income Statement > income Tax Expense
14301000
Annuals > 0 > income Statement > EBITDA
-32275000
Annuals > 0 > income Statement > operating Margin
14.22229120122855
Annuals > 0 > income Statement > total Other Income Expense Net
-287207000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
51428000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
251719000
Annuals > 0 > balance Sheet > inventories
127889000
Annuals > 0 > balance Sheet > total Current Assets
455020000
Annuals > 0 > balance Sheet > property Plant Equipment
409744000
Annuals > 0 > balance Sheet > total Assets
1221400000
Annuals > 0 > balance Sheet > payables
67126000
Annuals > 0 > balance Sheet > short Term Debt
42217000
Annuals > 0 > balance Sheet > long Term Debt
1035882000
Annuals > 0 > balance Sheet > total Liabilities
1634171000
Annuals > 0 > balance Sheet > equity
-412771000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-231864000
Annuals > 0 > cash Flow > depreciation
31301000
Annuals > 0 > cash Flow > change In Working Capital
-288644000
Annuals > 0 > cash Flow > cash From Operations
-236843000
Annuals > 0 > cash Flow > capital Expenditures
57000000
Annuals > 0 > cash Flow > cash From Investing
-18868000
Annuals > 0 > cash Flow > cash From Financing
297306000
Annuals > 0 > cash Flow > net Change In Cash
40271000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-0.8654077526372441
Annuals > 0 > ratios > PB
-3.1221117319288414
Annuals > 0 > ratios > ROE
56.17255088172376
Annuals > 0 > ratios > ROA
-18.983461601440972
Annuals > 0 > ratios > FCF
-293843000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-0.6000690243872554
Annuals > 0 > health Score
31
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
91434000
Annuals > 1 > income Statement > cost Of Revenue
160856000
Annuals > 1 > income Statement > gross Profit
-69422000
Annuals > 1 > income Statement > operating Expenses
285438000
Annuals > 1 > income Statement > operating Income
-354860000
Annuals > 1 > income Statement > interest Expense
134824000
Annuals > 1 > income Statement > pretax Income
-651049000
Annuals > 1 > income Statement > net Income
-551731000
Annuals > 1 > income Statement > eps
-2.4277900753619472
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
227256469
Annuals > 1 > income Statement > income Tax Expense
-99318000
Annuals > 1 > income Statement > EBITDA
-493672000
Annuals > 1 > income Statement > operating Margin
-388.10508126080015
Annuals > 1 > income Statement > total Other Income Expense Net
-296189000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
11157000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
87217000
Annuals > 1 > balance Sheet > inventories
74433000
Annuals > 1 > balance Sheet > total Current Assets
194842000
Annuals > 1 > balance Sheet > property Plant Equipment
356581000
Annuals > 1 > balance Sheet > total Assets
950090000
Annuals > 1 > balance Sheet > payables
80563000
Annuals > 1 > balance Sheet > short Term Debt
47708000
Annuals > 1 > balance Sheet > long Term Debt
922134000
Annuals > 1 > balance Sheet > total Liabilities
1882583000
Annuals > 1 > balance Sheet > equity
-932493000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-551731000
Annuals > 1 > cash Flow > depreciation
24210000
Annuals > 1 > cash Flow > change In Working Capital
26328000
Annuals > 1 > cash Flow > cash From Operations
-312185000
Annuals > 1 > cash Flow > capital Expenditures
46473000
Annuals > 1 > cash Flow > cash From Investing
-46340000
Annuals > 1 > cash Flow > cash From Financing
301319000
Annuals > 1 > cash Flow > net Change In Cash
-55270000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-2.4277900753619472
Annuals > 1 > ratios > PB
-1.1722378783433227
Annuals > 1 > ratios > ROE
59.16730742214686
Annuals > 1 > ratios > ROA
-58.071445863023506
Annuals > 1 > ratios > FCF
-358658000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-3.92258897127983
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
83029000
Annuals > 2 > income Statement > cost Of Revenue
64095000
Annuals > 2 > income Statement > gross Profit
18934000
Annuals > 2 > income Statement > operating Expenses
365376000
Annuals > 2 > income Statement > operating Income
-346442000
Annuals > 2 > income Statement > interest Expense
91438000
Annuals > 2 > income Statement > pretax Income
-551647000
Annuals > 2 > income Statement > net Income
-513580000
Annuals > 2 > income Statement > eps
-2.5974891679826158
Annuals > 2 > income Statement > dividends Per Share
184757000
Annuals > 2 > income Statement > shares Outstanding
197721710
Annuals > 2 > income Statement > income Tax Expense
-38067000
Annuals > 2 > income Statement > EBITDA
-439800000
Annuals > 2 > income Statement > operating Margin
-417.254212383625
Annuals > 2 > income Statement > total Other Income Expense Net
-205205000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
66427000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
71387000
Annuals > 2 > balance Sheet > inventories
71470000
Annuals > 2 > balance Sheet > total Current Assets
230736000
Annuals > 2 > balance Sheet > property Plant Equipment
268095000
Annuals > 2 > balance Sheet > total Assets
828443000
Annuals > 2 > balance Sheet > payables
49188000
Annuals > 2 > balance Sheet > short Term Debt
25079000
Annuals > 2 > balance Sheet > long Term Debt
744654000
Annuals > 2 > balance Sheet > total Liabilities
1392859000
Annuals > 2 > balance Sheet > equity
-564416000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-513580000
Annuals > 2 > cash Flow > depreciation
20409000
Annuals > 2 > cash Flow > change In Working Capital
-47890000
Annuals > 2 > cash Flow > cash From Operations
-312389000
Annuals > 2 > cash Flow > capital Expenditures
49002000
Annuals > 2 > cash Flow > cash From Investing
-63537000
Annuals > 2 > cash Flow > cash From Financing
424910000
Annuals > 2 > cash Flow > net Change In Cash
48871000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-2.5974891679826158
Annuals > 2 > ratios > PB
-1.685000824037589
Annuals > 2 > ratios > ROE
90.9931681596553
Annuals > 2 > ratios > ROA
-61.9934020807708
Annuals > 2 > ratios > FCF
-361391000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-4.352587650098158
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
36772000
Annuals > 3 > income Statement > cost Of Revenue
0
Annuals > 3 > income Statement > gross Profit
36772000
Annuals > 3 > income Statement > operating Expenses
272228000
Annuals > 3 > income Statement > operating Income
-235456000
Annuals > 3 > income Statement > interest Expense
112971000
Annuals > 3 > income Statement > pretax Income
-149198000
Annuals > 3 > income Statement > net Income
-101504000
Annuals > 3 > income Statement > eps
-3.248128
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
31250000
Annuals > 3 > income Statement > income Tax Expense
-47694000
Annuals > 3 > income Statement > EBITDA
-18031000
Annuals > 3 > income Statement > operating Margin
-640.313281844882
Annuals > 3 > income Statement > total Other Income Expense Net
86258000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
17556000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
53882000
Annuals > 3 > balance Sheet > inventories
39058000
Annuals > 3 > balance Sheet > total Current Assets
119816000
Annuals > 3 > balance Sheet > property Plant Equipment
205331000
Annuals > 3 > balance Sheet > total Assets
597977000
Annuals > 3 > balance Sheet > payables
28587000
Annuals > 3 > balance Sheet > short Term Debt
10066000
Annuals > 3 > balance Sheet > long Term Debt
398140000
Annuals > 3 > balance Sheet > total Liabilities
733589000
Annuals > 3 > balance Sheet > equity
-135612000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-101504000
Annuals > 3 > cash Flow > depreciation
18196000
Annuals > 3 > cash Flow > change In Working Capital
-6807000
Annuals > 3 > cash Flow > cash From Operations
-228170000
Annuals > 3 > cash Flow > capital Expenditures
40633000
Annuals > 3 > cash Flow > cash From Investing
-40633000
Annuals > 3 > cash Flow > cash From Financing
254831000
Annuals > 3 > cash Flow > net Change In Cash
-14133000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-3.248128
Annuals > 3 > ratios > PB
-1.1084011739374096
Annuals > 3 > ratios > ROE
74.84883343656904
Annuals > 3 > ratios > ROA
-16.974565911397928
Annuals > 3 > ratios > FCF
-268803000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-7.309991297726531
Annuals > 3 > health Score
31
Valuation > metrics > PE
21.3913
Valuation > metrics > PB
-8.169849042446666
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
2.9519752436878757
Profitability > metrics > ROA
-1.2078535946260005
Profitability > metrics > Net Margin
-0.04579080849122007
Profitability > final Score
6
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
0.03753550842549436
Risk > final Score
30
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.9259382175052657
Liquidity > metrics > Quick Ratio
1.5190081749036553
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
50
Prev Profitabilities > 0
47
Prev Profitabilities > 1
60
Prev Profitabilities > 2
32
Prev Risks > 0
32
Prev Risks > 1
31
Prev Risks > 2
30
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:22:29.987Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-05-06
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
0.0329
Earnings History > 0 > eps Difference
-0.0329
Earnings History > 0 > surprise Percent
-100
Earnings History > 1 > period
2025-12-31
Earnings History > 1 > report Date
2026-03-18
Earnings History > 1 > date
2025-12-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0
Earnings History > 1 > eps Estimate
-0.0833
Earnings History > 1 > eps Difference
0.0833
Earnings History > 1 > surprise Percent
100
Earnings History > 2 > period
2025-09-30
Earnings History > 2 > report Date
2025-11-12
Earnings History > 2 > date
2025-09-30
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.0174
Earnings History > 2 > eps Estimate
0.04
Earnings History > 2 > eps Difference
-0.0574
Earnings History > 2 > surprise Percent
-143.5
Earnings History > 3 > period
2025-06-30
Earnings History > 3 > report Date
2025-08-13
Earnings History > 3 > date
2025-06-30
Earnings History > 3 > before After Market
AfterMarket
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0.03
Earnings History > 3 > eps Estimate
-0.0023
Earnings History > 3 > eps Difference
0.0323
Earnings History > 3 > surprise Percent
1404.3478
Earnings History > 4 > period
2025-03-31
Earnings History > 4 > report Date
2025-05-08
Earnings History > 4 > date
2025-03-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
0.35
Earnings History > 4 > eps Estimate
0.03
Earnings History > 4 > eps Difference
0.32
Earnings History > 4 > surprise Percent
1066.6667
Earnings History > 5 > period
2024-12-31
Earnings History > 5 > report Date
2025-03-26
Earnings History > 5 > date
2024-12-31
Earnings History > 5 > before After Market
AfterMarket
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
-0.24
Earnings History > 5 > eps Estimate
-0.03
Earnings History > 5 > eps Difference
-0.21
Earnings History > 5 > surprise Percent
-700
Earnings History > 6 > period
2024-09-30
Earnings History > 6 > report Date
2024-11-13
Earnings History > 6 > date
2024-09-30
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.48
Earnings History > 6 > eps Estimate
-0.06
Earnings History > 6 > eps Difference
-0.42
Earnings History > 6 > surprise Percent
-700
Earnings History > 7 > period
2024-06-30
Earnings History > 7 > report Date
2024-08-15
Earnings History > 7 > date
2024-06-30
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
0.28
Earnings History > 7 > eps Estimate
-0.02
Earnings History > 7 > eps Difference
0.3
Earnings History > 7 > surprise Percent
1500
Earnings History > 8 > period
2024-03-31
Earnings History > 8 > report Date
2024-05-21
Earnings History > 8 > date
2024-03-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.89
Earnings History > 8 > eps Estimate
-0.08
Earnings History > 8 > eps Difference
-0.81
Earnings History > 8 > surprise Percent
-1012.5
Earnings History > 9 > period
2023-12-31
Earnings History > 9 > report Date
2024-03-20
Earnings History > 9 > date
2023-12-31
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-1.22
Earnings History > 9 > eps Estimate
0.04
Earnings History > 9 > eps Difference
-1.26
Earnings History > 9 > surprise Percent
-3150
Earnings History > 10 > period
2023-09-30
Earnings History > 10 > report Date
2023-11-28
Earnings History > 10 > date
2023-09-30
Earnings History > 10 > before After Market
AfterMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.82
Earnings History > 10 > eps Estimate
-0.07
Earnings History > 10 > eps Difference
-0.75
Earnings History > 10 > surprise Percent
-1071.4286
Earnings History > 11 > period
2023-06-30
Earnings History > 11 > report Date
2023-08-30
Earnings History > 11 > date
2023-06-30
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.14
Earnings History > 11 > eps Estimate
-0.14
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
0
Earnings History > 12 > period
2023-03-31
Earnings History > 12 > report Date
2023-05-19
Earnings History > 12 > date
2023-03-31
Earnings History > 12 > before After Market
BeforeMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-1.24
Earnings History > 12 > eps Estimate
-1.24
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
0
Earnings History > 13 > period
2022-12-31
Earnings History > 13 > report Date
2023-03-01
Earnings History > 13 > date
2022-12-31
Earnings History > 13 > before After Market
AfterMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-1.51
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
-1.51
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2022-09-30
Earnings History > 14 > report Date
2022-11-15
Earnings History > 14 > date
2022-09-30
Earnings History > 14 > before After Market
AfterMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.0346
Earnings History > 14 > eps Estimate
0.02
Earnings History > 14 > eps Difference
-0.0546
Earnings History > 14 > surprise Percent
-273
Earnings History > 15 > period
2022-06-30
Earnings History > 15 > report Date
2022-08-31
Earnings History > 15 > date
2022-06-30
Earnings History > 15 > before After Market
AfterMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.74
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
-0.74
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2022-03-31
Earnings History > 16 > report Date
2022-05-16
Earnings History > 16 > date
2022-03-31
Earnings History > 16 > before After Market
AfterMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-3.25
Earnings History > 16 > eps Estimate
-
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2021-12-31
Earnings History > 17 > report Date
2022-03-30
Earnings History > 17 > date
2021-12-31
Earnings History > 17 > before After Market
AfterMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-0.1264
Earnings History > 17 > eps Estimate
-
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2021-09-30
Earnings History > 18 > report Date
2021-11-15
Earnings History > 18 > date
2021-09-30
Earnings History > 18 > before After Market
AfterMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
0.0352
Earnings History > 18 > eps Estimate
-
Earnings History > 18 > eps Difference
0
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2021-06-30
Earnings History > 19 > report Date
2021-08-16
Earnings History > 19 > date
2021-06-30
Earnings History > 19 > before After Market
AfterMarket
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-0.0072
Earnings History > 19 > eps Estimate
-
Earnings History > 19 > eps Difference
0
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2021-03-31
Earnings History > 20 > report Date
2021-05-20
Earnings History > 20 > date
2021-03-31
Earnings History > 20 > before After Market
AfterMarket
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
0.2262
Earnings History > 20 > eps Estimate
-
Earnings History > 20 > eps Difference
0
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2020-12-31
Earnings History > 21 > report Date
2021-03-31
Earnings History > 21 > date
2020-12-31
Earnings History > 21 > before After Market
AfterMarket
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-0.2956
Earnings History > 21 > eps Estimate
-
Earnings History > 21 > eps Difference
0
Earnings History > 21 > surprise Percent
-
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAssessing Alvotech (ALVO) Valuation After FDA Setback And Securities Investigation Concerns simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$22.1667
Analyst Picks
Strong Buy
2
Buy
0
Hold
2
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 3.25% of the total shares of Alvotech
1.
Vanguard Total Intl Stock Index Inv(0.5014%)
since
2025/07/31
2.
Vanguard Emerging Mkts Stock Idx Inv(0.4416%)
since
2025/07/31
3.
T. Rowe Price International Discovery(0.3668%)
since
2025/07/31
4.
T. Rowe Price International Small-Cap Eq(0.3424%)
since
2025/06/30
5.
Eaton Vance Emerg & Frntr Countrs Eq I(0.2796%)
since
2025/07/31
6.
Vanguard Instl Ttl Intl Stk Mkt Idx TrII(0.2579%)
since
2025/07/31
7.
iShares Biotechnology ETF(0.2093%)
since
2025/08/31
8.
L&G Frontier Markets Eq Z USD Acc(0.1818%)
since
2025/07/31
9.
Eaton Vance Glbl Macro Abs Ret Advtg I(0.1552%)
since
2025/04/30
10.
T. Rowe Price Intl Small-Cap Eq Tr-C(0.0812%)
since
2025/06/30
11.
Vanguard FTSE All-Wld ex-US ETF(0.073%)
since
2025/07/31
12.
Eaton Vance Strategic Income Class C(0.0613%)
since
2025/04/30
13.
Fidelity Nasdaq Composite Index(0.0527%)
since
2025/07/31
14.
iShares Nasdaq US Biotech ETF USD Acc(0.0504%)
since
2025/08/31
15.
Schwab Emerging Markets Equity ETFâ„¢(0.0428%)
since
2025/08/30
16.
Vanguard Instl Ttl Intl Stck Mkt Idx Tr(0.0395%)
since
2025/07/31
17.
Eaton Vance Glbl Macr Absolute Return I(0.039%)
since
2025/04/30
18.
Morgan Stanley Global Macro Abs. Return(0.0287%)
since
2025/03/31
19.
Vanguard Total World Stock ETF(0.0244%)
since
2025/07/31
20.
SSGA Emerging Markets Equity Index(0.023%)
since
2025/08/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.0833
Date
2025-09-30
EPS Actual
-0.0174
EPS Estimate
0.04
EPS Difference
-0.0574
Surprise Percent
-143.5%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.